Effects of bortezomib on ponatinib-resistant Philadelphia chromosome-positive cells

Leuk Lymphoma. 2024 May;65(5):696-699. doi: 10.1080/10428194.2024.2309308. Epub 2024 Feb 1.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Bortezomib* / pharmacology
  • Drug Resistance, Neoplasm* / drug effects
  • Drug Resistance, Neoplasm* / genetics
  • Humans
  • Imidazoles* / pharmacology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / pathology
  • Philadelphia Chromosome / drug effects
  • Pyridazines* / pharmacology
  • Pyridazines* / therapeutic use

Substances

  • ponatinib
  • Pyridazines
  • Imidazoles
  • Bortezomib
  • Antineoplastic Agents